Oncolytics Biotech, Inc.

Twitter LinkedIn
  • Home
  • About
    • Our Company
    • Management Team
    • Board of Directors
  • Technology
    • What is Pelareorep?
    • What Does Pelareorep Do?
    • Delivery
    • Intellectual Property
    • Posters & Publications
    • Manufacturing
  • Clinical Trials
    • Clinical Development Plan
    • Collaborators
    • Pipeline
  • Media
    • Press Releases
    • Insights
  • Investors
    • Overview
    • Press Releases
    • Events & Presentations
    • Stock Information
    • Filings & Financials
    • Corporate Governance
    • FAQs
    • Email Alerts
    • IR Contacts
  • Contact
  • Careers

Press Releases

Investors

Investors

  • Overview
  • Press Releases
  • Events & Presentations
  • Stock Info
    • Snapshot
    • Quote (Nasdaq)
    • Charts (Nasdaq)
    • Historical Data (Nasdaq)
    • Quote (TSX)
    • Charts (TSX)
    • Historical Data (TSX)
    • Analyst Coverage
  • Filings & Financials
    • Reports
    • SEC Filings
    • SEDAR Filings
    • Tax Information (PFIC)
  • Corporate Governance
  • FAQs
  • Email Alerts
  • IR Contacts
Oct 27, 2020

Oncolytics Biotech® Collaborates with Roche and AIO to Initiate a Phase 1/2 Gastrointestinal Cancer Trial Combining Pelareorep with Roche's Anti-PD-L1 Checkpoint Inhibitor

Oct 19, 2020

Oncolytics Biotech® Appoints Richard Vile, Ph.D., to its Scientific Advisory Board

Oct 7, 2020

Oncolytics Biotech® to Participate in BIO Investor Forum Digital

Sep 1, 2020

Oncolytics Biotech® Announces Upcoming Presentations at Investor Conferences

Aug 26, 2020

Oncolytics Biotech® Doses First Patient in Phase 2 IRENE Study Evaluating Pelareorep-anti-PD-1 Combination Treatment in Triple-Negative Breast Cancer

Aug 10, 2020

Oncolytics Biotech® to Participate in Virtual Fireside Chat at the Canaccord Genuity 40th Annual Growth Conference

Aug 4, 2020

Oncolytics Biotech® Reports 2020 Second Quarter Financial Results and Operational Highlights

Jul 29, 2020

Oncolytics Biotech® to Host Conference Call to Discuss Second Quarter Financial Results and Operational Highlights

Jun 25, 2020

Oncolytics Biotech® Announces Investigator Sponsored Phase 2 Trial Evaluating Pelareorep-anti-PD-1 Combination Treatment in Triple-Negative Breast Cancer

Jun 23, 2020

Oncolytics Biotech® Doses First Patient in Phase 2 BRACELET-1 Study Evaluating Pelareorep-Based Combination Therapies in Metastatic Breast Cancer

RSS
    • 1...
    • 3
    • 4
    • 5
    • 6
    • 7
    • 8
    • 9
    • 10
    • 11
    • 12
    • ...59
    © 2023 Oncolytics Biotech, Inc. All Rights Reserved.
    Privacy Policy Disclaimer Sitemap